Flex-IT! Applying "platform trials" methodology to immunotherapy for food allergy in research and clinical practice

Douglas P. Mack,Julia Upton,Nandinee Patel,Paul J. Turner

DOI: https://doi.org/10.1016/j.jaip.2024.01.009

IF: 11.022

2024-01-13

The Journal of Allergy and Clinical Immunology In Practice

Abstract:There is an increasing trend in the management of food allergy towards active treatment using allergen immunotherapy (AIT). While AIT is efficacious, treatment-related adverse events are common, particularly with oral immunotherapy in those with high levels of allergen-specific IgE-sensitization. In clinical practice, these adverse events inevitably create challenges: clinicians and patients routinely face decisions whether to alter the dose itself, the frequency of dosing, the pace of escalation, or indeed discontinue AIT altogether. Flexibility is therefore needed to adapt treatment, particularly in clinical practice, so that participants are "treated-to-target". For example, this may entail a significant change in dosing protocol or even switching from one route of administration to another, in response to frequent adverse events. We refer to this approach as Flexible-Immunotherapy (Flex-IT). However, there is little evidence to inform clinicians as to what changes to treatment are most likely to result in treatment success. Classical clinical trials rely, by necessity, on relatively rigid updosing protocols. To provide an evidence base to optimize AIT, the food allergy community should adopt adaptive platform trials, where a "master protocol" facilitates more efficient evaluation, including longer-term outcomes of multiple interventions. Within a single clinical trial, participants are able to switch between different treatment arms; interventions can be added or dropped without compromising the integrity of the trial. Developing platform trials for food-AIT may initially be costly, but they represent a significant opportunity to grow the evidence base (with respect to both treatment outcomes and biomarker discovery) at scale. In addition, they could help understand longitudinal disease trajectories which are difficult to study in clinical trials for food allergy, due to the time needed to demonstrate changes in efficacy. Finally, their adoption would achieve greater collaboration and consistency in approaches to proactive management of food allergy in routine clinical practice. As a community, we need to actively pursue this with funders and established research collaborations, to deliver the very best outcomes for our patients and their families.

immunology,allergy